of a trial in partnership with the university of brasilia and the oswaldo cruz foundation of brazil showed that due to lower toxicity and acceptable efficacy, liposomal amphotericin b would be a more suitable first-line treatment for visceral leishmaniasis than standard treatment. in june 2022, the pan american health organization (paho) published new guidelines for the treatment of leishmaniasis in the americas, which recommend liposomal amphotericin b for the treatment of visceral leishmaniasis instead of pentavalent antimonials. 4-in-1 for paediatric hiv, 2022 this ‘4-in-1’ fixed-dose combination combines the protease inhibitors lopinavir and ritonavir with the nucleoside reverse transcriptase inhibitors (nrtis) lamivudine and abacavir for the treatment of paediatric hiv. the 4-in-1 is a significant improvement over currently available lopinavir-based regimens, because it is formulated as a granule-filled capsule, which is heat-stable, taste-masked, solid, and does not contain alcohol or inappropriate solvents. it was developed for infants and young children weighing from 3 to 25 kg, in partnership with cipla limited. it can be administered by opening the capsules and sprinkling the granules on soft food, water, or milk. the south african health products regulatory authority (sahpra) approved the 4-in-1 in june 2022. awards in 2013, dndi won the bbva foundation frontiers of knowledge award in the development cooperation category for developing and delivering new treatments for poverty-related diseases including chagas disease, sleeping sickness, malaria and leishmaniasis. dndi received the carlos slim health award in 2013. created in 2008 by the carlos slim foundation, the aim of the award is to distinguish the people and institutions who are committed to improving the levels of health among the population of latin america and the caribbean. in 2013, the rockefeller foundation asked the global community to nominate organizations and individuals who were making a difference for poor and vulnerable populations through innovation. from those nominations, and the votes of individuals around the world, the rockefeller foundation selected three winners of the 2013 next century innovators award. dndi was one of the awardees. on december 11, 2015, dndi won the national finep award for innovation. the award was in recognition of an innovative r&d model that has delivered a new antimalarial drug developed in brazil. dndi received the prize for innovation in 2017 and the ‘cuvée 2018 de la vigne des nations’ in 2018, both from the canton of geneva. the publication oral fexinidazole for late-stage african trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial published november 4, 2017 in the lancet was one of the two winners of the 2018 edition of the anne maurer-cecchini award. a short film about fexinidazole, a new treatment for sleeping sickness, was awarded the grand prix at the inaugural world health organization 'health for all' film festival in 2020. 'a doctor's dream' was produced by dndi with scholars and gentlemen, a production company from south africa. regional clinical trial platforms dndi works with partners in disease-endemic countries to strengthen existing clinical research capacity and build new capacity where necessary. dndi helped in the setting up of four regional disease-specific platforms in africa and latin america including the leishmaniasis east africa platform (leap) on leishmaniasis. the hat platform on sleeping sickness (human african trypanosomiasis), the chagas clinical research platform (ccrp), and the redeleish network on leishmaniasis in latin america and continues to work with them. their mission is to define patient needs, taking into consideration the local conditions, bring together key regional actors in the field of health, reinforce clinical capacities in endemic regions, address infrastructural requirements where necessary and provide on-site training. long-term objective as part of its strategic plan 2021-2028, dndi aims to deliver 15 to 18 new treatments, for a total of 25 new treatments in its first 25 years.